{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T14:22:04Z","timestamp":1790173324037,"version":"4.1.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejpn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Paediatric Neurology"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.ejpn.2022.04.004","type":"journal-article","created":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T21:38:10Z","timestamp":1650490690000},"page":"77-84","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Deflazacort dose optimization and safety evaluation in Duchenne muscular dystrophy (DOSE): A randomized, double-blind non-inferiority trial"],"prefix":"10.1016","volume":"38","author":[{"given":"Chaithanya","family":"Reddy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8552-2796","authenticated-orcid":false,"given":"Amol N.","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renu","family":"Suthar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveen","family":"Sankhyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9989-307X","authenticated-orcid":false,"given":"Titiksha","family":"Sirari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankit","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samiksha","family":"Bhattacharjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2951-8861","authenticated-orcid":false,"given":"Somya","family":"Saxena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5747-8975","authenticated-orcid":false,"given":"Arushi G.","family":"Saini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jitendra K.","family":"Sahu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ejpn.2022.04.004_bib1","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/ana.23528","article-title":"Evidence-based path to newborn screening for Duchenne muscular dystrophy","volume":"71","author":"Mendell","year":"2012","journal-title":"Ann. Neurol."},{"issue":"2","key":"10.1016\/j.ejpn.2022.04.004_bib2","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/oxfordjournals.bmb.a071623","article-title":"Clinical features and classification of the muscular dystrophies","volume":"36","author":"Gardner-Medwin","year":"1980","journal-title":"Br. Med. Bull."},{"issue":"5","key":"10.1016\/j.ejpn.2022.04.004_bib3","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/mus.26191","article-title":"Deflazacort versus prednisone\/prednisolone for maintaining motor function and delaying loss of ambulation: a post HOC analysis from the ACT DMD trial","volume":"58","author":"Shieh","year":"2018","journal-title":"Muscle Nerve"},{"issue":"1","key":"10.1016\/j.ejpn.2022.04.004_bib4","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/mus.27428","article-title":"Intermittent versus daily regimen of prednisolone in ambulatory boys with Duchenne muscular dystrophy: a randomized, open-label trial","volume":"65","author":"Kochar","year":"2022","journal-title":"Muscle Nerve"},{"issue":"3","key":"10.1016\/j.ejpn.2022.04.004_bib5","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S1474-4422(18)30024-3","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management","volume":"17","author":"Birnkrant","year":"2018","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.ejpn.2022.04.004_bib6","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12883-019-1304-8","article-title":"Variability and trends in corticosteroid use by male United States participants with Duchenne muscular dystrophy in the Duchenne Registry","volume":"19","author":"Cowen","year":"2019","journal-title":"BMC Neurol."},{"issue":"2","key":"10.1016\/j.ejpn.2022.04.004_bib7","first-page":"121","article-title":"Improvement of survival in Duchenne Muscular Dystrophy: retrospective analysis of 835 patients","volume":"31","author":"Passamano","year":"2012","journal-title":"Acta Myol."},{"issue":"5","key":"10.1016\/j.ejpn.2022.04.004_bib8","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1097\/WCO.0000000000000739","article-title":"Update in duchenne and becker muscular dystrophy","volume":"32","author":"Waldrop","year":"2019","journal-title":"Curr. Opin. Neurol."},{"issue":"10119","key":"10.1016\/j.ejpn.2022.04.004_bib9","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(17)32160-8","article-title":"Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study","volume":"391","author":"McDonald","year":"2018","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.ejpn.2022.04.004_bib10","article-title":"Corticosteroids for the treatment of Duchenne muscular dystrophy","author":"Matthews","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"issue":"1","key":"10.1016\/j.ejpn.2022.04.004_bib11","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/mus.26736","article-title":"Deflazacort vs prednisone treatment for Duchenne muscular dystrophy: a meta-analysis of disease progression rates in recent multicenter clinical trials","volume":"61","author":"McDonald","year":"2020","journal-title":"Muscle Nerve"},{"issue":"24","key":"10.1016\/j.ejpn.2022.04.004_bib12","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1056\/NEJM198906153202405","article-title":"Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy","volume":"320","author":"Mendell","year":"1989","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ejpn.2022.04.004_bib13","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1001\/archneur.1991.00530160047012","article-title":"Prednisone in Duchenne dystrophy. A randomized, controlled trial defining the time course and dose response. Clinical Investigation of Duchenne Dystrophy Group","volume":"48","author":"Griggs","year":"1991","journal-title":"Arch. Neurol."},{"issue":"1","key":"10.1016\/j.ejpn.2022.04.004_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40360-016-0111-8","article-title":"Deflazacort: therapeutic index, relative potency and equivalent doses versus other corticosteroids","volume":"18","author":"Parente","year":"2017","journal-title":"BMC Pharmacol. Toxicol."},{"issue":"9","key":"10.1016\/j.ejpn.2022.04.004_bib15","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1002\/1097-4598(200009)23:9<1344::AID-MUS4>3.0.CO;2-F","article-title":"A\u00a0multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy","volume":"23","author":"Bonifati","year":"2000","journal-title":"Muscle Nerve"},{"issue":"20","key":"10.1016\/j.ejpn.2022.04.004_bib16","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1212\/WNL.0000000000003217","article-title":"Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy","volume":"87","author":"Griggs","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.ejpn.2022.04.004_bib17","author":"FDA"},{"issue":"4","key":"10.1016\/j.ejpn.2022.04.004_bib18","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1474-4422(18)30025-5","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management","volume":"17","author":"Birnkrant","year":"2018","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/j.ejpn.2022.04.004_bib19","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S1474-4422(18)30026-7","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespan","volume":"17","author":"Birnkrant","year":"2018","journal-title":"Lancet Neurol."},{"issue":"3","key":"10.1016\/j.ejpn.2022.04.004_bib20","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/mus.23905","article-title":"The 6-minute walk test and other clinical endpoints in duchenne muscular dystrophy: reliability, concurrent validity, and minimal clinically important differences from a multicenter study","volume":"48","author":"McDonald","year":"2013","journal-title":"Muscle Nerve"},{"issue":"4","key":"10.1016\/j.ejpn.2022.04.004_bib21","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1002\/mus.21544","article-title":"The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophy","volume":"41","author":"McDonald","year":"2010","journal-title":"Muscle Nerve"},{"issue":"6","key":"10.1016\/j.ejpn.2022.04.004_bib22","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1002\/mus.21808","article-title":"The 6-minute walk test in Duchenne\/Becker muscular dystrophy: longitudinal observations","volume":"42","author":"McDonald","year":"2010","journal-title":"Muscle Nerve"},{"issue":"5","key":"10.1016\/j.ejpn.2022.04.004_bib23","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.4103\/0028-3886.241363","article-title":"Commonly available outcome measures for use in Indian boys with Duchenne muscular dystrophy","volume":"66","author":"Arora","year":"2018","journal-title":"Neurol. India"},{"issue":"10","key":"10.1016\/j.ejpn.2022.04.004_bib24","doi-asserted-by":"crossref","first-page":"e108205","DOI":"10.1371\/journal.pone.0108205","article-title":"Long term natural history data in ambulant boys with Duchenne muscular dystrophy: 36-month changes","volume":"9","author":"Pane","year":"2014","journal-title":"PLoS One"},{"issue":"32","key":"10.1016\/j.ejpn.2022.04.004_bib25","doi-asserted-by":"crossref","first-page":"5121","DOI":"10.1200\/JCO.2007.12.4784","article-title":"Patient-reported outcomes and the evolution of adverse event reporting in oncology","volume":"25","author":"Trotti","year":"2007","journal-title":"J.\u00a0Clin. Oncol."},{"issue":"9","key":"10.1016\/j.ejpn.2022.04.004_bib26","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.nmd.2016.05.016","article-title":"Categorizing natural history trajectories of ambulatory function measured by the 6-minute walk distance in patients with Duchenne muscular dystrophy","volume":"26","author":"Mercuri","year":"2016","journal-title":"Neuromuscul. Disord."},{"issue":"5","key":"10.1016\/j.ejpn.2022.04.004_bib27","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1212\/WNL.0b013e318227b164","article-title":"Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy","volume":"77","author":"Escolar","year":"2011","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.ejpn.2022.04.004_bib28","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1515\/jpem-2020-0680","article-title":"Bone density and bone health alteration in boys with Duchenne Muscular Dystrophy: a prospective observational study","volume":"34","author":"Suthar","year":"2021","journal-title":"J.\u00a0Pediatr. Endocrinol. Metab."},{"issue":"7","key":"10.1016\/j.ejpn.2022.04.004_bib29","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1093\/cid\/ciaa105","article-title":"Concurrent initiation of hepatitis C and opioid use disorder treatment in people who inject drugs","volume":"71","author":"Rosenthal","year":"2020","journal-title":"Clin. Infect. Dis."},{"issue":"5","key":"10.1016\/j.ejpn.2022.04.004_bib30","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/mus.26161","article-title":"Longitudinal timed function tests in Duchenne muscular dystrophy: ImagingDMD cohort natural history","volume":"58","author":"Arora","year":"2018","journal-title":"Muscle Nerve"},{"issue":"14","key":"10.1016\/j.ejpn.2022.04.004_bib31","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1056\/NEJMra1510063","article-title":"Challenges in the design and interpretation of noninferiority trials","volume":"377","author":"Mauri","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"8","key":"10.1016\/j.ejpn.2022.04.004_bib32","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.nmd.2013.05.006","article-title":"Ambulatory capacity and disease progression as measured by the 6-minute-walk-distance in Duchenne muscular dystrophy subjects on daily corticosteroids","volume":"23","author":"Goemans","year":"2013","journal-title":"Neuromuscul. Disord."},{"issue":"10","key":"10.1016\/j.ejpn.2022.04.004_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0164684","article-title":"Collaborative Trajectory Analysis P. Individualized prediction of changes in 6-minute walk distance for patients with duchenne muscular dystrophy","volume":"11","author":"Goemans","year":"2016","journal-title":"PLoS One"},{"issue":"13","key":"10.1016\/j.ejpn.2022.04.004_bib34","doi-asserted-by":"crossref","first-page":"e1312","DOI":"10.1212\/WNL.0000000000008168","article-title":"Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle function","volume":"93","author":"Hoffman","year":"2019","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.ejpn.2022.04.004_bib35","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ejpn.2005.06.004","article-title":"Functional ability and muscle force in healthy children and ambulant Duchenne muscular dystrophy patients","volume":"9","author":"Beenakker","year":"2005","journal-title":"Eur. J. Paediatr. Neurol."},{"issue":"5","key":"10.1016\/j.ejpn.2022.04.004_bib36","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/mus.26334","article-title":"Timed function tests have withstood the test of time as clinically meaningful and responsive endpoints in duchenne muscular dystrophy","volume":"58","author":"McDonald","year":"2018","journal-title":"Muscle Nerve"},{"issue":"230","key":"10.1016\/j.ejpn.2022.04.004_bib37","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008873","article-title":"Exon-skipping therapy: a roadblock, detour, or bump in the road?","volume":"6","author":"Hoffman","year":"2014","journal-title":"Sci. Transl. Med."},{"issue":"5","key":"10.1016\/j.ejpn.2022.04.004_bib38","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1097\/WCO.0000000000000243","article-title":"Duchenne muscular dystrophy: clinical trials and emerging tribulations","volume":"28","author":"Shieh","year":"2015","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.ejpn.2022.04.004_bib39","author":"Randomized"},{"key":"10.1016\/j.ejpn.2022.04.004_bib40","author":"Duchenne Muscular Dystrophy"},{"issue":"4","key":"10.1016\/j.ejpn.2022.04.004_bib41","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.nmd.2006.01.010","article-title":"Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade","volume":"16","author":"Biggar","year":"2006","journal-title":"Neuromuscul. Disord."},{"issue":"5","key":"10.1016\/j.ejpn.2022.04.004_bib42","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1302\/1863-2548.14.200156","article-title":"d'Amato C. Efficacy of corticosteroid in decreasing scoliosis and extending time to loss of ambulation in a single clinic: an effectiveness trial","volume":"14","author":"Sussman","year":"2020","journal-title":"J.\u00a0Child. Orthop."},{"issue":"9","key":"10.1016\/j.ejpn.2022.04.004_bib43","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1007\/s12098-020-03384-y","article-title":"The quest for the prediction of steroid responsiveness in duchenne muscular dystrophy","volume":"87","author":"Suthar","year":"2020","journal-title":"Indian J. Pediatr."}],"container-title":["European Journal of Paediatric Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090379822000605?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090379822000605?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T18:39:51Z","timestamp":1761071991000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1090379822000605"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":43,"alternative-id":["S1090379822000605"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpn.2022.04.004","relation":{},"ISSN":["1090-3798"],"issn-type":[{"value":"1090-3798","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Deflazacort dose optimization and safety evaluation in Duchenne muscular dystrophy (DOSE): A randomized, double-blind non-inferiority trial","name":"articletitle","label":"Article Title"},{"value":"European Journal of Paediatric Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpn.2022.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}